On 20 February 2020, Beroni Group Limited (OTCQX: BNIGF; NSX: BTG), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, announced its collaboration with Tianjin University in China to develop a medical solution for the coronavirus (COVID-19) epidemic. A team of scientists from Tianjin University and from Beroni Group is now working to develop a rapid detection method and precision- driven treatment of COVID-19 caused by SARS-CoV-2 infection using nanobody-based technology.
This announcement can be found at https://www.nsx.com.au/ftp/news/021737862.PDF.
Since this announcement was published, Beroni Group has been mentioned in various media sites in the international market, notably the following:
American Pharmaceutical Review